journal cover

Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients

The American Journal of Managed Care

Aug 8, 2015

John HornbergerBruce Quinn

PMID: 26247576

Abstract

To describe the lifetime outcomes and economic implications of combinatorial pharmacogenomic (CPGx) testing versus treatment as usual (TAU) psychopharmacologic medication selection for a representative major depressive disorder patient who has not responded to previous treatment(s). Mar...read more

Mentioned in this Paper

Laboratory Procedures
Meta Analysis (Statistical Procedure)
Depressive Disorder
Triacetyluridine
Pharmacogenomics
Pharmacogenomic Test
Analysis
Clinical Research
Mental Depression
Synthetic Peptide Combinatorial Library
2
47
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Pharmacogenetics & Pharmacogenomics

Pharmacogenetics and pharmacogenomics (pgx) are rapidly growing fields that aim to elucidate the genetic basis for the interindividual differences in drug response. Here is the latest research on pharmacogenetics and pharmacogenomics.

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer

Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial

Lung Cancer : Journal of the International Association for the Study of Lung CancerMarch 26, 2015
John HornbergerRay D Page
© 2020 Meta ULC. All rights reserved

Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients

The American Journal of Managed Care

Aug 8, 2015

John HornbergerBruce Quinn

PMID: 26247576

DOI:

Abstract

To describe the lifetime outcomes and economic implications of combinatorial pharmacogenomic (CPGx) testing versus treatment as usual (TAU) psychopharmacologic medication selection for a representative major depressive disorder patient who has not responded to previous treatment(s). Mar...read more

Mentioned in this Paper

Laboratory Procedures
Meta Analysis (Statistical Procedure)
Depressive Disorder
Triacetyluridine
Pharmacogenomics
Pharmacogenomic Test
Analysis
Clinical Research
Mental Depression
Synthetic Peptide Combinatorial Library
2
47

Similar Papers Found In These Feeds

Pharmacogenetics & Pharmacogenomics

Pharmacogenetics and pharmacogenomics (pgx) are rapidly growing fields that aim to elucidate the genetic basis for the interindividual differences in drug response. Here is the latest research on pharmacogenetics and pharmacogenomics.

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer

Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial

Lung Cancer : Journal of the International Association for the Study of Lung CancerMarch 26, 2015
John HornbergerRay D Page
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.
/papers/cost-effectiveness-of-combinatorial/26247576